236 related articles for article (PubMed ID: 10594565)
1. Serum levels of soluble Fas ligand in patients with silicosis.
Tomokuni A; Otsuki T; Isozaki Y; Kita S; Ueki H; Kusaka M; Kishimoto T; Ueki A
Clin Exp Immunol; 1999 Dec; 118(3):441-4. PubMed ID: 10594565
[TBL] [Abstract][Full Text] [Related]
2. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.
Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Harris J; Hoi AY; Mackay F; Morand EF
Lupus Sci Med; 2020 Jun; 7(1):. PubMed ID: 32546562
[TBL] [Abstract][Full Text] [Related]
3. [Levels and clinic significance of serum soluble Fas and soluble Fas ligand in coal workers' pneumoconiosis].
Yuan BJ; Liu ZZ; Ding XR; Zou JM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 Feb; 24(2):96-8. PubMed ID: 16600114
[TBL] [Abstract][Full Text] [Related]
4. Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours.
Tomokuni A; Aikoh T; Matsuki T; Isozaki Y; Otsuki T; Kita S; Ueki H; Kusaka M; Kishimoto T; Ueki A
Clin Exp Immunol; 1997 Nov; 110(2):303-9. PubMed ID: 9367417
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of cases with silicosis using the parameters related to Fas-mediated apoptosis.
Otsuki T; Ichihara K; Tomokuni A; Sakaguchi H; Aikoh T; Matsuki T; Isozaki Y; Hyodoh F; Kusaka M; Kita S; Ueki A
Int J Mol Med; 1999 Oct; 4(4):407-11. PubMed ID: 10493983
[TBL] [Abstract][Full Text] [Related]
6. Soluble Fas mRNA is dominantly expressed in cases with silicosis.
Otsuki T; Sakaguchi H; Tomokuni A; Aikoh T; Matsuki T; Kawakami Y; Kusaka M; Ueki H; Kita S; Ueki A
Immunology; 1998 Jun; 94(2):258-62. PubMed ID: 9741350
[TBL] [Abstract][Full Text] [Related]
7. Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients.
Otsuki T; Tomokuni A; Sakaguchi H; Aikoh T; Matsuki T; Isozaki Y; Hyodoh F; Ueki H; Kusaka M; Kita S; Ueki A
Clin Exp Immunol; 2000 Feb; 119(2):323-7. PubMed ID: 10632670
[TBL] [Abstract][Full Text] [Related]
8. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
Mouawad R; Khayat D; Soubrane C
Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
[TBL] [Abstract][Full Text] [Related]
9. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
10. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.
Nozawa K; Kayagaki N; Tokano Y; Yagita H; Okumura K; Hasimoto H
Arthritis Rheum; 1997 Jun; 40(6):1126-9. PubMed ID: 9182923
[TBL] [Abstract][Full Text] [Related]
11. Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus.
Liphaus BL; Kiss MHB; Carrasco S; Palmeira P; Goldenstein-Schainberg C; Carneiro-Sampaio M
Clin Rheumatol; 2017 Dec; 36(12):2847-2852. PubMed ID: 28378099
[TBL] [Abstract][Full Text] [Related]
12. Circulating soluble Fas ligand correlates with disease activity in Graves' hyperthyroidism.
Wang CY; Zhong WB; Chang TC; Tsai YF
Metabolism; 2002 Jun; 51(6):769-73. PubMed ID: 12037733
[TBL] [Abstract][Full Text] [Related]
13. Examination of soluble Fas (sFas) and soluble Fas ligand (sFasL) in patients with burns.
Yamada Y; Endo S; Nakae H; Makabe H; Sato N; Wakabayashi G; Kitamura M; Inada K; Sato S
Burns; 2003 Dec; 29(8):799-802. PubMed ID: 14636754
[TBL] [Abstract][Full Text] [Related]
14. Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.
Kuwano K; Maeyama T; Inoshima I; Ninomiya K; Hagimoto N; Yoshimi M; Fujita M; Nakamura N; Shirakawa K; Hara N
Respirology; 2002 Mar; 7(1):15-21. PubMed ID: 11896896
[TBL] [Abstract][Full Text] [Related]
15. Detection of alternatively spliced variant messages of Fas gene and mutational screening of Fas and Fas ligand coding regions in peripheral blood mononuclear cells derived from silicosis patients.
Otsuki T; Sakaguchi H; Tomokuni A; Aikoh T; Matsuki T; Isozaki Y; Hyodoh F; Kawakami Y; Kusaka M; Kita S; Ueki A
Immunol Lett; 2000 May; 72(2):137-43. PubMed ID: 10841950
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system.
Wang XZ; Chen XC; Chen YX; Zhang LJ; Li D; Chen FL; Chen ZX; Chen HY; Tao QM
World J Gastroenterol; 2003 Dec; 9(12):2671-5. PubMed ID: 14669310
[TBL] [Abstract][Full Text] [Related]
17. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C
Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
[TBL] [Abstract][Full Text] [Related]
18. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
[TBL] [Abstract][Full Text] [Related]
19. [Dysregulation of Fas and related molecules in silicosis patients].
Takata-Tomokuni A; Miura Y; Hyodoh F; Katsuyama H; Ueki A; Otsuki T
Nihon Eiseigaku Zasshi; 2005 Jan; 60(1):30-7. PubMed ID: 15773295
[TBL] [Abstract][Full Text] [Related]
20. Serum sFas/sFasL ratio in systemic lupus erythematosus (SLE) is a function of age.
Turi MC; D'Urbano M; Celletti E; Alessandri C; Valesini G; Paganelli R
Arch Gerontol Geriatr; 2009; 49 Suppl 1():221-6. PubMed ID: 19836636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
